All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Universal CAR-T cell therapies are expected to transform the landscape of cancer immunotherapy and enhance patient results. Creative Biolabs has earned a strong reputation in the field of cellular and gene therapy research, innovation, and advancement. Our team of specialists is committed to advancing novel therapeutic solutions for UCAR-T production aimed at addressing a wide range of cancer types.
Our Universal CAR-T Cell Production Service follows a streamlined workflow that maximizes efficiency and minimizes production costs. The process can be summarized as follows:
UCAR-T derived from peripheral blood mononuclear cells (PBMCs), umbilical cord blood (UCB), and renewable stem cells such as induced pluripotent stem cells (iPSCs) or embryonic stem can be produced.
Various gene editing methods are available, including but not limited to Transcription Activator-like Nucleases (TALEN), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9).
UCAR-T can also be manufactured with non-gene editing methods to minimize the off-target effect induced by gene editing, with which the expression of the target genes were interfered.
UCAR-T can also be manufactured with non-gene editing methods to minimize the off-target effect induced by gene editing, with which the expression of the target genes were interfered.
We offer a range of UCAR-T cell editing strategies designed to enhance their functionality, ultimately making them more efficient at targeting and eradicating cancer cells through various approaches.
Our service offers customization of Universal CAR-T cells for various cancer types. Whether it's hematologic malignancies like leukemia or solid tumors like breast cancer, our team can adapt the Universal CAR-T cells to target the specific antigens associated with the disease.
Please do not hesitate to contact us if you have any questions about the process.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION